서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Title

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하
All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 54,081 to 54,100 of 146,736

Issue DateTitle / Author(s) / CitationFileAltmetrics
2017-10
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
DOI
2020-07
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
DOI
2018-02
Phase I pharmacokinetic study of nivolumab in Korean patients with advanced solid tumors
DOI
2020-01
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16-or 18-Positive Recurrent Cervical Cancer
DOI
2015-10
Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer
DOI
2016-01
Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors
DOI
2021-12
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
DOI
2015-10
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
DOI
2016-03
Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors
DOI
2013-12
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
DOI
2019-06
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
DOI
2002-01
Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer

Wu, Hong Gyun; Bang, Yung-Jue; Choi, Eun Kyung; Ahn, Yong Chan; Kim, Young Whan; Lim, Tae-Hwan; Suh, Cheolwon; Park, Keunchil; Park, Charn Il

International Journal of Radiation Oncology Biology Physics, Vol.52 No.1, pp.75-80

DOI
2016-07
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
DOI
2015-08
Phase I/II study of weekly Oraxol for the second-line treatment of patients with metastatic or recurrent gastric cancer
DOI
2019-07
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
DOI
2018-11
Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer
DOI
2018-09
Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer
DOI
2012-09
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
DOI
1999-10
Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma
DOI
2008-04
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
link
12700 2701 2702 2703 2704 2705 27067337